Yong-Chul Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7908731/publications.pdf

Version: 2024-02-01

112	2,710	186265	223800
papers	citations	28 h-index	46 g-index

114	114	114	3812
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Derivatives of the Triazoloquinazoline Adenosine Antagonist (CGS15943) Are Selective for the Human A₃Receptor Subtype. Journal of Medicinal Chemistry, 1996, 39, 4142-4148.	6.4	154
2	MIPs are ancestral ligands for the sex peptide receptor. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6520-6525.	7.1	147
3	Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-Î² during Murine Colitis. Cell Reports, 2016, 17, 3219-3232.	6.4	116
4	Synthesis and structureâ€“activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorganic and Medicinal Chemistry, 2006, 14, 237-246.	3.0	115
5	Subdermal Flexible Solar Cell Arrays for Powering Medical Electronic Implants. Advanced Healthcare Materials, 2016, 5, 1572-1580.	7.6	112
6	Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Experimental Eye Research, 2010, 91, 425-432.	2.6	93
7	Structureâ^'Activity Relationships of Pyridoxal Phosphate Derivatives as Potent and Selective Antagonists of P2X1Receptors. Journal of Medicinal Chemistry, 2001, 44, 340-349.	6.4	86
8	P2X7 receptor antagonists: a patent review (2010â€“2015). Expert Opinion on Therapeutic Patents, 2017, 27, 257-267.	5.0	84
9	5,5â€²-Substituted Indirubin-3â€²-oxime Derivatives as Potent Cyclin-Dependent Kinase Inhibitors with Anticancer Activity. Journal of Medicinal Chemistry, 2010, 53, 3696-3706.	6.4	79
10	A Pyridoxine Cyclic Phosphate and Its 6-Azoaryl Derivative Selectively Potentiate and Antagonize Activation of P2X1 Receptors. Journal of Medicinal Chemistry, 1998, 41, 2201-2206.	6.4	64
11	Induction of apoptosis by a novel indirubin-5-nitro-3â€²-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3948-3952.	2.2	55
12	Differentiation of cutaneous melanoma from surrounding skin using laser-induced breakdown spectroscopy. Biomedical Optics Express, 2016, 7, 57.	2.9	50
13	ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes. Scientific Reports, 2017, 7, 44186.	3.3	42
14	Pheophorbide-a conjugates with cancer-targeting moieties for targeted photodynamic cancer therapy. Bioorganic and Medicinal Chemistry, 2015, 23, 1453-1462.	3.0	41
15	Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly. Nature Communications, 2019, 10, 2184.	12.8	41
16	Synthesized Pheophorbide aâ€mediated photodynamic therapy induced apoptosis and autophagy in human oral squamous carcinoma cells. Journal of Oral Pathology and Medicine, 2013, 42, 17-25.	2.7	40
17	Synthesis and therapeutic evaluation of an aptideâ€“docetaxel conjugate targeting tumor-associated fibronectin. Journal of Controlled Release, 2014, 178, 118-124.	9.9	39
18	Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production. Scientific Reports, 2019, 9, 11587.	3.3	37

#	Article	IF	Citations
19	Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2033-2037.	2.2	36
20	Synthesis and structure-activity relationships of pyridoxal-6-arylazo-5?-phosphate and phosphonate derivatives as P2 receptor antagonists. , 1998, 45, 52-66.		35
21	Solid-Phase Synthesis of Tetrahydro-1,4-benzodiazepine-2-one Derivatives as a Î²-Turn Peptidomimetic Library. ACS Combinatorial Science, 2004, 6, 207-213.	3.3	35
22	Benzofuroindole Analogues as Potent BK_{Ca} Channel Openers. ChemBioChem, 2005, 6, 1745-1748.	2.6	35
23	Discovery of Novel 2,5-Dioxoimidazolidine-Based P2X₇Receptor Antagonists as Constrained Analogues of KN62. Journal of Medicinal Chemistry, 2015, 58, 2114-2134.	6.4	35
24	A3 adenosine receptors: Protective vs. damaging effects identified using novel agonists and antagonists. , 1998, 45, 113-124.		34
25	Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion. Journal of Medicinal Chemistry, 2016, 59, 7410-7430.	6.4	34
26	Natural product derivative BIO promotes recovery after myocardial infarction via unique modulation of the cardiac microenvironment. Scientific Reports, 2016, 6, 30726.	3.3	34
27	Design, synthesis and anticancer activity of fluorocyclopentenyl-purines and â€“ pyrimidines. European Journal of Medicinal Chemistry, 2018, 155, 406-417.	5.5	34
28	Acyl-hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors. Drug Development Research, 1999, 47, 178-188.	2.9	33
29	Structureâ^'Activity Relationship Studies of Spinorphin as a Potent and Selective Human P2X3Receptor Antagonist. Journal of Medicinal Chemistry, 2007, 50, 4543-4547.	6.4	31
30	Synthesis and structureâ€“activity relationships of novel, substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 antagonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 954-958.	2.2	31
31	Acyclic Analogues of Deoxyadenosine 3â€˜,5â€˜-Bisphosphates as P2Y1 Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 43, 746-755.	6.4	29
32	5-Nitro-5â€²-hydroxy-indirubin-3â€²-oxime (AGM130), an indirubin-3â€²-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2015, 79, 122-131.	4.0	28
33	Anti-tumor activity of noble indirubin derivatives in human solid tumor models In Vitro. Archives of Pharmacal Research, 2009, 32, 915-922.	6.3	27
34	Indirubin-3â€²-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling. Cancer Letters, 2008, 265, 215-225.	7.2	26
35	Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2719-2723.	2.2	26
36	Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: synthesis of ligands for somatostatin receptors. Bioorganic and Medicinal Chemistry, 2003, 11, 5059-5068.	3.0	25

#	Article	IF	Citations
37	Actions of a series of PPADS analogs at P2X1 and P2X3 receptors. Drug Development Research, 2001, 53, 281-291.	2.9	24
38	Structureâ€“Activity Relationships and Optimization of 3,5-Dichloropyridine Derivatives As Novel P2X₇ Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 3687-3698.	6.4	24
39	Discovery of Potent Antiallodynic Agents for Neuropathic Pain Targeting P2X3 Receptors. ACS Chemical Neuroscience, 2017, 8, 1465-1478.	3.5	24
40	Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. European Journal of Medicinal Chemistry, 2018, 151, 462-481.	5.5	24
41	Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the m6A Methylation of RNA in Acute Myeloid Leukemia Cells. Pharmaceuticals, 2022, 15, 440.	3.8	24
42	Antiviral Activity of Coxsackievirus B3 3C Protease Inhibitor in Experimental Murine Myocarditis. Journal of Infectious Diseases, 2012, 205, 491-497.	4.0	23
43	Structureâ€“activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3632-3636.	2.2	22
44	Discovery of orally active indirubin-3â€²-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia. European Journal of Medicinal Chemistry, 2020, 195, 112205.	5.5	21
45	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives. Journal of Medicinal Chemistry, 2021, 64, 8272-8286.	6.4	21
46	Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 6071-6074.	2.2	20
47	Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7â€“NMDA Receptor Antagonists. Molecules, 2018, 23, 230.	3.8	20
48	Mapping of cutaneous melanoma by femtosecond laser-induced breakdown spectroscopy. Journal of Biomedical Optics, 2018, 24, 1.	2.6	20
49	Electrophysiological Characterization of Benzofuroindole-Induced Potentiation of Large-Conductance Ca2+-Activated K+ Channels. Molecular Pharmacology, 2006, 69, 1007-1014.	2.3	19
50	Development of potent inhibitors of the coxsackievirus 3C protease. Biochemical and Biophysical Research Communications, 2007, 358, 7-11.	2.1	19
51	Synthesis and structureâ€“activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 571-575.	2.2	17
52	Combinatorial Library Synthesis and Biological Evaluation of Pyrazolo[4,3â€e][1,4]diazepine as a Potential Privileged Structure. ChemMedChem, 2009, 4, 733-737.	3.2	16
53	Novel small molecule activators of Î²-catenin-mediated signaling pathway: structureâ€“activity relationships of indirubins. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2282-2284.	2.2	16
54	2,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors. European Journal of Medicinal Chemistry, 2016, 120, 202-216.	5.5	16

#	Article	IF	Citations
55	Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells. Bioorganic and Medicinal Chemistry, 2006, 14, 6752-6758.	3.0	15
56	Design and synthesis of potent and selective P2X3 receptor antagonists derived from PPADS as potential pain modulators. European Journal of Medicinal Chemistry, 2013, 70, 811-830.	5.5	15
57	Synthesis and structureâ€“activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6053-6058.	2.2	13
58	Development of anti-coxsackievirus agents targeting 3C protease. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6952-6956.	2.2	13
59	The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3. Bioorganic and Medicinal Chemistry, 2016, 24, 5036-5046.	3.0	13
60	Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells. Anticancer Research, 2016, 36, 6381-6388.	1.1	13
61	Benserazide, the first allosteric inhibitor of Coxsackievirus B3 3C protease. FEBS Letters, 2015, 589, 1795-1801.	2.8	12
62	Urinary Bladder-Relaxant Effect of Kurarinone Depending on Potentiation of Large-Conductance Ca²⁺-Activated K⁺ Channels. Molecular Pharmacology, 2016, 90, 140-150.	2.3	12
63	Combinatorial synthesis and biological evaluation of peptide-binding GPCR-targeted library. Bioorganic Chemistry, 2009, 37, 90-95.	4.1	11
64	Localization of a Site of Action for Benzofuroindole-Induced Potentiation of BK_{Ca} Channels. Molecular Pharmacology, 2012, 82, 143-155.	2.3	11
65	Nanoparticle-encapsulated P2X7 receptor antagonist in a pH-sensitive polymer as a potential local drug delivery system to acidic inflammatory environments. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4197-4202.	2.2	11
66	5-diphenylacetamido-indirubin-3â€²-oxime as a novel mitochondria-targeting agent with anti-leukemic activities. Molecular Carcinogenesis, 2016, 55, 611-621.	2.7	11
67	Escape from adamantane: Scaffold optimization of novel P2X7 antagonists featuring complex polycycles. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 759-763.	2.2	11
68	Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal Cancer Cells. Immune Network, 2017, 17, 110.	3.6	11
69	Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia. Oncotarget, 2018, 9, 924-936.	1.8	11
70	Synthesis and structureâ€“activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists. Bioorganic and Medicinal Chemistry, 2013, 21, 2643-2650.	3.0	10
71	Preparation and therapeutic evaluation of paclitaxel-conjugated low-molecular-weight chitosan nanoparticles. Macromolecular Research, 2014, 22, 805-808.	2.4	10
72	Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with In Vitro Anti-Tumor Effects. Biomolecules and Therapeutics, 2019, 27, 216-221.	2.4	10

#	Article	IF	Citations
73	Inhibition of ecto-apyrase and ecto-ATPase by pyridoxal phosphate-related compounds. Drug Development Research, 2000, 51, 153-158.	2.9	9
74	Immunosuppressive Effects of Subglutinol Derivatives. ChemMedChem, 2012, 7, 218-222.	3.2	9
75	Structureâ€“activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists. European Journal of Medicinal Chemistry, 2015, 106, 180-193.	5.5	9
76	Discovery of substituted indole derivatives as allosteric inhibitors of<scp>m⁶Aâ€RNA</scp>methyltransferase,<scp>METTL3</scp>â€14 complex. Drug Development Research, 2022, , .	2.9	9
77	A novel indirubin derivative that increases somatic cell plasticity and inhibits tumorigenicity. Bioorganic and Medicinal Chemistry, 2019, 27, 2923-2934.	3.0	8
78	Characterization of protoberberine analogs employed as novel human P2X7 receptor antagonists. Toxicology and Applied Pharmacology, 2011, 252, 192-200.	2.8	7
79	Discovery and structureâ€“activity relationships of pyrazolodiazepine derivatives as the first small molecule agonists of the Drosophila sex peptide receptor. Bioorganic and Medicinal Chemistry, 2015, 23, 1808-1816.	3.0	7
80	Solid-Phase Synthesis of Quinolinone Library. ACS Combinatorial Science, 2015, 17, 60-69.	3.8	7
81	Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents. Journal of Medicinal Chemistry, 2021, 64, 5500-5518.	6.4	7
82	Elemental analysis of tissue pellets for the differentiation of epidermal lesion and normal skin by laser-induced breakdown spectroscopy. Biomedical Optics Express, 2016, 7, 1626.	2.9	6
83	Discovery and structureâ€“activity relationship studies of quinolinone derivatives as potent IL-2 suppressive agents. Bioorganic and Medicinal Chemistry, 2016, 24, 5357-5367.	3.0	6
84	Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity. Investigational New Drugs, 2017, 35, 733-741.	2.6	6
85	AI-based prediction of new binding site and virtual screening for the discovery of novel P2X3 receptor antagonists. European Journal of Medicinal Chemistry, 2022, 240, 114556.	5.5	6
86	5â€Nitroâ€5â€²hydroxyâ€indirubinâ€3â€²oxime Is a Novel Inducer of Somatic Cell Transdifferentiation. Archiv Der Pharmazie, 2014, 347, 806-818.	4.1	5
87	Homology modeling and molecular docking studies of Drosophila and Aedes sex peptide receptors. Journal of Molecular Graphics and Modelling, 2016, 66, 115-122.	2.4	5
88	Discovery of Novel Biased Opioid Receptor Ligands through Structureâ€Based Pharmacophore Virtual Screening and Experiment. ChemMedChem, 2019, 14, 1783-1794.	3.2	5
89	Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer. Pharmaceuticals, 2021, 14, 38.	3.8	5
90	Establishment of an assay for P2X7 receptor-mediated cell death. Molecules and Cells, 2006, 22, 198-202.	2.6	5

#	Article	IF	Citations
91	Validation of a liquid chromatographyâ€triple quadrupole mass spectrometric method for the determination of 5â€nitroâ€5â€²â€hydroxyâ€indirubinâ€3â€²â€oxime (AGMâ€130) in human plasma and its application to microdose clinical trial. Biomedical Chromatography, 2016, 30, 323-329.	1.7	4
92	Contrast agent free detection of bowel perforation using chlorophyll derivatives from food plants. Chemical Physics Letters, 2016, 643, 10-15.	2.6	4
93	Chemical characterization and biological activity data for a novel indirubin derivative, LDD-1819. Data in Brief, 2019, 25, 104373.	1.0	4
94	Synthesis and Structureâ€“Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents. Molecules, 2022, 27, 1337.	3.8	4
95	Effects of KRC-108 on the Aurora A activity and growth of colorectal cancer cells. Biochemical and Biophysical Research Communications, 2015, 461, 605-611.	2.1	3
96	Indirubin-3-monoxime Prevents Tumorigenesis in Breast Cancer through Inhibition of JNK1 Activity. Biomedical Science Letters, 2021, 27, 134-141.	0.3	3
97	Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A2B adenosine receptor antagonists. Biochemical Pharmacology, 2022, 200, 115027.	4.4	3
98	A Highly Sensitive Liquid Chromatographyâ€“Electrospray Ionizationâ€“Time of Flight/Mass Spectrometric Assay for the Quantitation of 4-Beta-Hydroxycholesterol and Its Application toin vivoCytochrome P450 3a Induction by AGM-130. Journal of Liquid Chromatography and Related Technologies, 2015, 38, 1675-1680.	1.0	2
99	Pyrazolodiazepine derivatives with agonist activity toward Drosophila RYamide receptor. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5116-5118.	2.2	2
100	Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor. Oncology Letters, 2017, 14, 1347-1354.	1.8	2
101	Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Development Research, 2000, 49, 253-259.	2.9	2
102	Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation. Bioorganic and Medicinal Chemistry, 2022, 68, 116862.	3.0	2
103	DEVELOPMENT OF A LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD FOR THE DETERMINATION OF INDIRUBIN-5-NITRO-3â€²-MONOXIME, A NOVEL CDK INHIBITOR, IN RAT PLASMA. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 2175-2187.	1.0	1
104	Discovery of novel purine-based heterocyclic P2X7 receptor antagonists. Bioorganic Chemistry, 2015, 61, 58-65.	4.1	1
105	Discovery of LDDâ€‘1075 as a potent FLT3 inhibitor. Oncology Letters, 2019, 17, 4735-4741.	1.8	1
106	Development of UHPLC-MS/MS Method for Indirubin-3â€²-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats. Molecules, 2020, 25, 2039.	3.8	1
107	Differentiation of cutaneous melanoma from surrounding skin using laser-induced breakdown spectroscopy. , 2016, , .		1
108	Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 55, 128451.	2.2	1

#	Article	IF	Citations
109	Discovery of indirubin-3â€²-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia. European Journal of Medicinal Chemistry, 2022, 237, 114356.	5.5	1
110	Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain. Pharmaceuticals, 2022, 15, 407.	3.8	0
111	Discovery of 5-methyl-1H-benzo[d]imidazole derivatives as novel P2X3 Receptor Antagonists. Bioorganic and Medicinal Chemistry Letters, 2022, , 128820.	2.2	0
112	Abstract 5445: New discovery and development of transglutaminase 2 inhibitor. Cancer Research, 2022, 82, 5445-5445.	0.9	0